OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
19
Results
Show all
Save search
Copy query
Show results for
Unknown
(19)
Publication Date
Release Date
2021
(7)
2022
(5)
2025
(2)
2023
(2)
2024
(1)
2020
(1)
2017
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer.
Not available
S-EPMC5736236
|
biostudies-literature
Cite
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
Not available
S-EPMC11797383
|
biostudies-literature
Cite
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Not available
S-EPMC7787219
|
biostudies-literature
Cite
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
Not available
S-EPMC8693692
|
biostudies-literature
Cite
Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7.
Not available
S-EPMC8185188
|
biostudies-literature
Cite
SARS-CoV-2 evolution during treatment of chronic infection.
Not available
S-EPMC7610568
|
biostudies-literature
Cite
Genomic reconstruction of the SARS-CoV-2 epidemic in England.
Not available
S-EPMC8674138
|
biostudies-literature
Cite
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8830904
|
biostudies-literature
Cite
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8598213
|
biostudies-literature
Cite
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
Not available
S-EPMC9333998
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets